The relationship between LAMP3 and the response to anti‐PD‐1 monotherapy and anti‐PD‐1/anti‐CTLA‐4 combined therapy in melanoma patients showed that the survival of patients with high LAMP3 expression was better than those with low LAMP3 expression (p < 0.05) (Figure 6D). This evidence concerns the gene CTLA4 and melanoma.